After a Breakthrough Therapy guidance meeting with the US Food & Drug Administration (FDA), Sage Therapeutics announced plans to launch 3 additional studies of its investigational drug zuranolone.
If successful, the studies could lead toward 3 distinct indications for the medication: for use as an oral therapy in women with postpartum depression, for use as an acute rapid response therapy in patients with major depressive disorder (MDD) when co-initiated with new standard antidepressant therapy, and for use as an episodic therapy in patients with MDD.
“Following FDA guidance, Sage has several potential pathways to bring zuranolone to patients, if we are successful, with two pathways that would represent unique indications that we believe we can progress quickly and efficiently, while in tandem we pursue our original approach to develop zuranolone for the episodic treatment of depression,” said Jeff Jonas, MD, chief executive officer of Sage Therapeutics, in a company press release.
The 3 new placebo-controlled studies are set to begin this year and are in addition to 3 already completed efficacy studies for the rapid-acting, short-course treatment. Each of the new studies will evaluate a 2-week course of zuranolone 50 mg; in a trial testing its efficacy as acute treatment for MDD with a new standard antidepressant, it will be co-initiated with an open-label selective serotonin reuptake inhibitor. Results are expected in 2021.
Zuranolone, an investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, was previously granted a Breakthrough Therapy designation by the FDA.
Sage Therapeutics announces development plan for zuranolone (SAGE-217) following breakthrough therapy guidance meeting with the U.S. Food & Drug Administration [press release]. Cambridge, Massachusetts: Sage Therapeutics; March 18, 2020.
- ^ major depressive disorder (www.psychcongress.com)
- ^ Exploring the Role of GABA in Psychiatric Treatment (www.psychcongress.com)
- ^ Sage Therapeutics announces development plan for zuranolone (SAGE-217) following breakthrough therapy guidance meeting with the U.S. Food & Drug Administration [press release]. Cambridge, Massachusetts: Sage Therapeutics; March 18, 2020. (investor.sagerx.com)
Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.
Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.
We are Internet Investors, Developers, and Franchisers – operating a content network of several thousand sites while federating 100+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $100M in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Contact us to learn how we can help you with your online marketing and/or site maintenance.